Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FORANE vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Induction and maintenance of general anesthesia,Sedation for mechanical ventilation in intensive care
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
Context-sensitive half-life: 2-5 minutes after short exposure; prolonged to 30-60 minutes after prolonged administration due to accumulation in fat and muscle. Terminal elimination half-life: 0.5-1 hour.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily hepatic via CYP2E1; also undergoes glucuronidation and defluorination.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Primarily exhaled unchanged via lungs (>95%); <5% metabolized in liver to fluoride ions and other metabolites, which are excreted renally.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
~40% bound to plasma proteins (mainly albumin).
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
Vd: 1.5-2.0 L/kg, reflecting distribution to highly perfused tissues (brain, heart, liver, kidneys) and subsequent redistribution to muscle and fat.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
100% via inhalation.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
No adjustment required.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Use with caution; reduce dose in severe hepatic impairment (Child-Pugh C).
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Induction: 1-4% inspired; Maintenance: 0.5-2% inspired.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Reduce inspired concentrations by 25-50% due to increased sensitivity.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
None
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of malignant hyperthermia,Respiratory depression,Hypotension,Hepatotoxicity with repeated use or in susceptible patients,Nephrotoxicity due to fluoride ions
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Known hypersensitivity to isoflurane or other halogenated agents,Known or suspected genetic susceptibility to malignant hyperthermia
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
No specific food interactions are documented for isoflurane. However, patients should follow standard preoperative fasting guidelines (e.g., NPO for 8 hours prior to elective surgery) to reduce aspiration risk during anesthesia.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters: known to cause dose-dependent maternal hypotension and uterine relaxation, which may reduce placental perfusion; use only if clearly needed.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Isoflurane is excreted into breast milk in minimal amounts; M/P ratio is approximately 0.85. After inhalational anesthesia, the concentration in milk is low and rapidly cleared. The American Academy of Pediatrics considers it compatible with breastfeeding. However, it is recommended to discard milk for 24 hours post-procedure due to sedation and potential metabolites.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustment is required for pregnancy, but due to increased volume of distribution and decreased protein binding, a slightly lower dose may achieve desired anesthetic depth. Maintenance of uterine perfusion pressure is critical; avoid hypotension. The minimum alveolar concentration (MAC) is decreased by approximately 25% in pregnancy.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
FORANE (isoflurane) is a potent inhalational anesthetic with rapid onset and offset due to low blood-gas solubility. It causes dose-dependent respiratory depression and hypotension via peripheral vasodilation. Monitor end-tidal CO2 and arterial blood pressure closely. Avoid in patients with known or suspected malignant hyperthermia susceptibility. Use a calibrated vaporizer to deliver precise concentrations (1-3% for induction, 0.5-2% for maintenance).
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
This medication is for hospital use only and will be administered by an anesthesia provider.,You may experience drowsiness, dizziness, or confusion after waking from anesthesia.,Do not drive or operate machinery for at least 24 hours after receiving this drug.,Inform your doctor if you have a personal or family history of malignant hyperthermia.,Report any muscle rigidity, fever, or dark urine to your healthcare provider immediately.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FORANE vs ACTIQ, answered by our medical review team.
FORANE is a Inhalational Anesthetic that works by Enhances GABA-A receptor activity and inhibits glutamate receptors, leading to neuronal hyperpolarization and anesthesia.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FORANE and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FORANE is: Induction: 0.5-3% inspired; Maintenance: 0.5-2% inspired.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FORANE and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FORANE is classified as Category C. FORANE (isoflurane) is classified as FDA Category C. In first trimester, animal studies show fetal malformations at high doses; human data insufficient. Second and third trimesters. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.